These viruses are divided into 2 groups (high or low risk) based on their oncogenic potential. The epidemiologic evidence that links HPV infection with cervical cancer includes data from case series, case-control and cohort studies. 8 In a large case series of 1000 cervical cancer cases in 22 countries, HPV DNA was detected in 99.7% of specimens. Case-control studies in 22 countries (sponsored by the International Agency for Research on Cancer) demonstrated consistently high odds ratios (ORs) for the risk of cervical cancer associated with persistent HPV infection (squamous cell carcinoma OR 90.0, adenocarcinoma OR 81.3). 8 In a 10-year cohort study of 20 810 women, the cumulative incidence of cervical intraepithelial neoplasia (grade 3) among women positive for HPV type 16 was 17.2% (95% confidence interval [CI] 11.5%-22.9%), and the incidence among women positive for HPV type 18 was 13.6% (95% CI 3.6%-23.7%). However, the risk among women who tested positive for high-risk HPV types other than types 16 and 18 was 3.0% (95% CI 1.9%-4.2%). The 10-year incidence of cervical intraepithelial neoplasia (grade 3) among women negative for oncogenic high-risk HPV infections was 0.8% (95% CI, 0.6%-1.1%).
9
This study provides a conservative estimate of risk, given the aggressive management of grade 1 and 2 cervical intraepithelial neoplasia lesions among the trial cohort. In addition to the epidemiologic evidence, the biologic mechanism of HPV carcinogenesis has been clearly delineated. 8 Globally, HPV types 16 and 18 account for 65%-77% of cervical cancers. HPV types 16 and 18 account for 41%-57% of high-grade cervical squamous intraepithelial lesions, 15%-32% of low-grade squamous intraepithelial lesions and 8%-19% of atypical squamous cells of undetermined significance. 10 Six HPV genotypes (types 31, 33, 35, 45, 52 and 58) account for an additional 20% of cervical cancers worldwide.
10
HPV infections are also associated with other genitourinary cancers (e.g., anal, penile, vaginal, vulvar), head and neck cancers (e.g., conjunctivae, mouth, oropharynx, larynx) and nonmalignant
Human papillomavirus vaccines launch a new era in cervical cancer prevention
Public Health -Perspectives on HPV 
Key points
• Each year in Canada there are about 1300 new cases and about 400 deaths caused by cervical cancer • About 40%-50% of cervical cancers occur in women who undergo routine cervical cytology screening • HPV is the most common sexually transmitted infection • HPV infection can cause cervical cancer and contributes to other cancers of the genitourinary tract, head and neck • Two prophylactic vaccines, Gardasil and Cervarix, offer protection against HPV types 16 and 18. These 2 genotypes are responsible for about 70% of cervical cancers • These vaccines protect against the precursors of cervical cancer (cervical intraepithelial neoplasia, grade 2 and higher). Proof of whether they protect against cervical cancer will take many years of follow-up • Gardasil protects against genital warts caused by HPV types 6 and 11 • Vaccine-induced antibody levels are much higher than those produced by natural infections. Immunity lasts for at least 5.5 years • Routine cytology screening is still required, because the vaccines do not protect against all oncogenic types of HPV • Gardasil is recommended for females aged 9-26 years. Cervarix is not yet available in Canada Exposure factors
• Increased number of sexual partners
• Early age of first intercourse
• Never being married
Endogenous factors
• Oral contraceptive use
• Immunosuppression secondary to infection or therapy
Cervical microenvironment factors
• Sexually transmitted infections diseases (e.g., genital warts, recurrent respiratory papillomatosis). 8,10-13 Of genital warts, 90%-100% of cases are caused by HPV types 6 and 11, although 20%-50% of lesions may be coinfected with high-risk types of HPV.
12 The International Agency for Research on Cancer has declared certain high-risk HPV genotypes, including HPV types 16 and 18, as group 1 carcinogens and has declared low-risk HPV types 6 and 11 as possible carcinogens (group 2b).
11
Infection with a high-risk type of HPV is a necessary, but not sufficient, cause of cervical cancer. The development of a precancerous lesion (squamous intraepithelial lesion) from a persistent HPV infection can take from 1 to 10 years, and the development of invasive cervical cancer can take an additional 10 years.
14 Thus, there is a long lag period from infection to invasive disease. Cofactors that contribute to disease progression include a history of smoking, long-term use of oral contraceptives, high parity and sexually transmitted infections.
8
The global annual incidence of cervical cancer ranges from 56.9/100 000 in Zimbabwe to less than 10/100 000 in developed countries including Canada, Switzerland and the Netherlands (Figure 1) . 13 Each year in Canada there are about 1300 cases of cervical cancer and about 400 deaths attributed to this disease. 15 The lifetime risk of cervical cancer among Canadian women is 0.7%, or 1 in 138 women. 15 Although the agestandardized incidence rates of cervical cancer in Canada have been reduced by half since the 1970s (primarily due to cervical cytology [i.e., Papanicolaou smear] screening programs), the decline in cervical cancer incidence rates has plateaued in the last decade.
15 Sensitivity of Pap smear screening programs for the detection of precancerous lesions varies widely;
16 thus, about 40% of cervical cancers in British Columbia (personal communication, Dr. Andy Coldman, BC Cancer Agency, 2007) and 50% of cervical cancers in the United States are detected in women who are routinely screened.
17

HPV vaccine development and clinical trial issues
Identification of HPV as an etiologic link to cervical cancer in the early 1990s stimulated the race for creation of an HPV vaccine. Vaccine development has involved attention to the design of vaccine components (e.g., antigen expression, choice of adjuvants, formulation and patent rights) and the development of serologic tests to measure immunity and tests to detect the specific type of HPV infection.
18
Interpretation of the immune response induced by the HPV vaccines is complicated by 2 factors. First, serologic correlates of immunity to HPV infection are unknown. For example, the minimum antibody threshold at which an individual is protected from natural HPV infections is unknown, as is how this level compares with vaccine-induced antibody titres. In addition, antibody titres from GlaxoSmithKline and Merck cannot be directly compared because the companies use different serologic assays. These assays have not been validated against each other or against an international standard, as the latter has not been developed.
19
Vaccine trials have examined a number of end points, including transient and persistent (lasting 4 months or longer) HPV infection, abnormal Pap smear results, histology (e.g., grade 1-3 cervical intraepithelial neoplasia lesions, adenocarcinoma in situ, cancer of the cervix and other genital sites) and other end points related to HPV types covered and not covered by the vaccine. Trials could not assess cervical cancer alone as an outcome, given the lengthy delay between HPV infection and onset of cervical cancer and the fact that the standard of care for precancerous cervical lesions (cervical intraepithelial neoplasia, grade 2-3) precludes watchful waiting. Thus, the World Health Organization advocates assessment of vaccine efficacy against the following disease outcomes: persistent infection (6 months or longer) and cervical intraepithelial neoplasia (grade 2 or higher).
20
HPV vaccines
Gardasil is a quadrivalent vaccine that offers protection against HPV types 6 and 11, which are responsible for 90% of genital warts, and HPV types 16 and 18, which are associated with 70% of cervical cancers. This vaccine is formulated with a classic alum adjuvant. Data on this vaccine's safety, immunogenicity, efficacy and effectiveness are now available from 5-year phase 2 21-23 and 3-year phase 3 [24] [25] [26] [27] trials that included 20 000 participants.
Cervarix is a bivalent vaccine that protects against HPV types 16 and 18.
The vaccine is formulated with a new ASO4 adjuvant that contains monophosphoryl lipid A, a derivative of bacterial cell walls. ASO4 is also incorporated in Fendrix (hepatitis B vaccine) and a candidate vaccine against herpes simplex virus, neither of which are approved for use in Canada. Data are available from 5-year phase 2 and 15-month phase 3 trials that included 18 000 participants. [28] [29] [30] [31] A comparison of the characteristics of Gardasil and Cervarix is provided in Table 1 . Table 2 provides data on the immune response to and efficacy of Gardasil and Cervarix from published phase 2 and 3 trials. Immune response data are derived from trial participants who had not been exposed to the HPV genotypes covered by the vaccines at trial enrolment through to completion of the 3-dose immunization series (per-protocol efficacy population). Efficacy data are derived from trial participants who are naive to the HPV genotypes covered by the vaccine at enrolment and who received 1 dose or more of the vaccine (intention-totreat population). Per-protocol efficacy analysis represents "a perfect world," where all vaccine doses are given on time and before the individual has been exposed to HPV. In contrast, intention-to-treat analysis represents a "real world" scenario, where the vaccine schedule has not necessarily been adhered to and the individual may be exposed to HPV before being fully vaccinated.
Clinical trial outcomes
Immune response among young women (16-26 years)
23 At 24-months follow-up, over 96% of participants in the Gardasil trial were seropositive for HPV types 6, 11 and 16; however, only 68% of participants were seropositive for HPV type 18. 25 The significance of this reduction remains unclear given that immune memory is induced by the vaccine.
32
Cervarix-induced antibody titres follow the same profile as Gardasil, with 2 differences. The 18-month plateau level is many-fold higher than the levels induced by natural infection and, after 51-53 months, 100% of women were seropositive for both HPV types 16 and 18. 
33-35
This response is more pronounced for younger adolescents (aged 9-13 years). 34 Two doses of Gardasil (0 and 2 months) in adolescents aged 10-15 years produced antibody titres that were equivalent to those produced by 3 doses (0, 2 and 6 months) in women aged 16-26 years for 3 of the 4 vaccine genotypes;
33 however, the sustainability of this response over time has not been evaluated.
Vaccine efficacy
Among the per-protocol efficacy population, a full series of both vaccines is highly efficacious (96%) in preventing persistent infection with the HPV genotypes 23, 29 covered by the vaccine. Efficacy against persistent infection in an intention-to-treat population was 94% and 80% for Gardasil and Cervarix respectively. 25, 31 Vaccine efficacy for precancerous lesions (cervical intraepithelial neoplasia, grade 2 or higher) caused by HPV types 16 and 18 is 98% for Gardasil and 90% for Cervarix.
27,31
In addition, Gardasil offers 100% protection against vulvar intraepithelial neoplasia (grade 2-3) and vaginal intraepithelial neoplasia (grade 2-3) caused by HPV types 16 and 18.
26 Gardasil is also 96% efficacious in preventing genital warts.
36
In the Cervarix trials, modest cross protection was documented against infection of HPV type 45 (vaccine efficacy 60%) and, to a lesser extent, against HPV types 31 and 52 (vaccine efficacy 36% and 32% respectively). 31 The cross-protective effect of Gardasil has not yet been reported. HPV types 45, 31 and 52 are estimated to cause 12% of cervical cancers.
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Phase 3 data on the effectiveness of Gardasil among women aged [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] years are available. 24, 25, 27 The general trial population included all women who met the inclusion criteria (less than 5 life-time sexual partners) who potentially had been infected with HPV types covered by the vaccine at or before trial enrolment and who may have received fewer than 3 vaccine doses. In this population, vaccine efficacy against cervical disease was very low (vaccine-specific types 44%-55%, all types 17%-20%), thus demonstrating that the vaccine is not effective if adminstered to women who are already infected with vaccine-specific HPV types. These results highlight 2 issues. First, Gardasil should be used as a prophylactic vaccine and therefore should be offered to females before they are at risk of HPV infection. Second, all vaccinated females should continue to participate in Pap smear screening programs because they remain at risk of adverse gynecological outcomes from other high-risk HPV genotypes. • Vaccine efficacy 93.5% (95% CI 83%-98%) 23 • Vaccine efficacy 80.4% (95% CI 70%-87%) 31 Cervical intraepithelial neoplasia (grade 2 or higher) related to HPV types 16 and 18
• Vaccine efficacy 98% (95% CI 93%-100%) 27 • Vaccine efficacy 90.4% (95% CI 53%-99%) 31 Vaginal and vulvar intraepithelial neoplasia (grade 2 or higher) related to HPV types 16 and 18
• Vaccine efficacy 97% (95% CI 79%-100%) 26 • No data Persistent infection † of HPV type 45
• No data • Vaccine efficacy 59.9% (95% CI 3%-85%) 31 Persistent infection † of HPV type 31
• No data • Vaccine efficacy 36.1% (95% CI 0.5%-60%) 31 Protection from genital warts • Vaccine efficacy 96% (95% CI 86%-99%) 24 • No data Note: CI = confidence interval. *All disease outcomes are derived from intention-to-treat analyses for populations that were seronegative and polymerase chain reaction negative at enrolment for all HPV genotypes covered by the vaccine and had received at least 1 dose of the vaccine. †Persistent infection was defined as 4 months in the Gardasil trial and as 6 months in the Cervarix trial.
Vaccine safety
Both vaccines have a good safety profile. Cervarix and Gardasil both produced local reactions that were 6%-8% more frequent than reactions produced by an alum placebo. 28, 36 Cervarixinduced local reactions were 12%-22% more frequent than reactions produced by an investigational hepatitis A vaccine. 31 There was no difference noted in the frequency of systemic adverse events among those who received the vaccine or the placebo.
28,31,36
Gardasil is not approved for pregnant women, although data on 1900 women who became pregnant during the vaccine trials indicate that adverse events (including congenital anomalies) were similar among recipients of the vaccine and the placebo.
36,37
Data are available on 1350 pregnancies that occurred during the Cervarix phase 3 trial. 31 No differences in pregnancy outcomes were reported among those who received the vaccine or the placebo.
Recommendations
The National Advisory Committee on Immunization recently released its recommendations for the use of Gardasil in females aged 9-26 years.
3 Because of limited data, Gardasil is not recommended for females less than 9 years of age, males (all ages) or pregnant women. Because of a lack of efficacy data, Gardasil is not recommended for women over 26 years of age; however, women in this group may receive the vaccine after an individual consultation. Full recommendations can be viewed at www.naci.gc.ca.
Recommendations for Cervarix use will be made once this vaccine has been reviewed by the regulators and is approved for use in Canada.
Discussion
Cervical cancer ranks as the 12th most common type of incidental cancer among Canadian women and ranks second globally. 13 In 2002, worldwide there were an estimated 493 000 cases and 274 000 deaths due to cervical cancer. 13 Although substantial reductions in cervical cancer incidence and mortality have been made in developed countries (primarily because of the implementation of cervical cytology screening programs), the absence of such programs in the developing world, barriers to access and acceptability of cytology screening in population subgroups in the developed world and poor test performance (high false-negative rate) contribute to this high mortality rate.
Gardasil and Cervarix are both empty virus-like particle vaccines that were created using recombinant technology. Both vaccines are safe. Both vaccines provide protection against infection by HPV types 16 and 18, 2 oncogenic HPV genotypes that cause about 70% of cervical cancers. Both vaccines protect against high-grade cervical disease (cervical intraepithelial neoplasia, grade 2 and higher). In addition, Gardasil trials have demonstrated that this vaccine is efficacious against high-grade vaginal and vulvar lesions. Gardasil also offers protection against the 2 HPV genotypes that are responsible for about 90% of genital warts. The preliminary data from the phase 3 trials of Cervarix have demonstrated 2 differences from Gardasil: a slightly lower efficacy against cervical disease and modest cross protection against 3 additional oncogenic genotypes that are responsible for 12% of cervical cancers. Given that these 2 vaccines contain identical virus-like particle antigens against oncogenic types of HPV, long-term follow-up studies will help to discern the significance of these differences.
Information available on HPV vaccines is evolving rapidly, with new peer-reviewed publications becoming available each month. In addition, there are a number of trials planned or underway that will contribute to our understanding of these vaccines. Trials of Gardasil among men are under way, and there are plans to test a 3-dose regimen of Gardasil among people who are immunocompromised and to test a 2-dose regimen among adolescents. GlaxoSmithKline has announced plans to conduct a head-to-head comparison of Cervarix and Gardasil, and both GlaxoSmithKline and Merck are conducting trials involving older women and are planning trials of secondgeneration vaccines that will offer protection against additional high-risk HPV genotypes.
Although Gardasil and Cervarix have demonstrated favourable beginnings, there are still a number of knowledge gaps (Box 2).
38 Planned long-term follow-up of phase 3 trials and population-based studies 39, 40 are required to fill in these knowledge gaps.
Conclusion
Both Cervarix and Gardasil represent superb technological achievements. We strongly recommend a universal publicly funded vaccination program aimed at immunizing adolescent females before they are at risk of HPV infection. Although there are knowledge gaps, especially about long-term efficacy, this is not unusual at the outset of any new vaccine program. Careful ongoing evaluation of the performance of the HPV-vaccine program and of HPV-infection epidemiology and surveillance of HPV-induced cancers will be essential. We look forward to trial data supporting efficacy in males so that young males can also benefit from the potential protection afforded by this vaccine.
Box 2: Knowledge gaps
• Will HPV vaccines affect cervical cancer incidence and mortality?
• Is the priming vaccine series sufficient or will a booster dose be required?
• Will exposure to wild-type HPV contribute to natural boosting?
• Will other HPV genotypes fill the niche previously filled by HPV types 16 and 18?
• How will the vaccination program affect current cytology screening programs?
• Will current cytology screening programs need to be adapted to identify vaccine failures?
• Are there rare but serious adverse effects of vaccination that have not yet been detected?
